These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients. Rao V; Dharia I; Gibilisco J; Kirelik D; Baumgartner S; Negreira K; Chawla K; Dave J; Kallus S; Belfaqeeh OA; Borum ML J Natl Med Assoc; 2024 Feb; 116(1):13-15. PubMed ID: 38036315 [TBL] [Abstract][Full Text] [Related]
7. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942 [TBL] [Abstract][Full Text] [Related]
8. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020. Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972 [TBL] [Abstract][Full Text] [Related]
9. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816 [TBL] [Abstract][Full Text] [Related]
10. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Gisbert JP; Chaparro M J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. Borren NZ; Tan W; Colizzo FP; Luther J; Garber JJ; Khalili H; van Der Woude CJ; Ananthakrishnan AN J Crohns Colitis; 2020 Mar; 14(3):309-315. PubMed ID: 31504365 [TBL] [Abstract][Full Text] [Related]
13. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care? Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825 [TBL] [Abstract][Full Text] [Related]
14. Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients. Cohen-Mekelburg S; Gold S; Schneider Y; Dennis M; Oromendia C; Yeo H; Michelassi F; Scherl E; Steinlauf A Dig Dis Sci; 2019 Jan; 64(1):196-203. PubMed ID: 29876778 [TBL] [Abstract][Full Text] [Related]
15. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease. Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280 [TBL] [Abstract][Full Text] [Related]
16. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Jung YS; Han M; Park S; Cheon JH Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070 [TBL] [Abstract][Full Text] [Related]
17. Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. Caron B; Habert A; Bonsack O; Camara H; Jeanbert E; Parigi TL; Netter P; Danese S; Peyrin-Biroulet L United European Gastroenterol J; 2024 Jun; 12(5):605-613. PubMed ID: 38594841 [TBL] [Abstract][Full Text] [Related]
18. Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease. Yang JY; Lund JL; Funk MJ; Hudgens MG; Lewis JD; Kappelman MD; Am J Gastroenterol; 2023 Sep; 118(9):1638-1647. PubMed ID: 37053548 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139 [TBL] [Abstract][Full Text] [Related]
20. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab. Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]